CD40 and myeloid sarcoma: A lower expression of CD40, being a costimulator of T-cell activation, has been associated with increased risk of MS development, despite that the same CD40 variant may be associated with the reduced risk of other inflammatory ADs, and could be consistent with other, for example immunoregulatory, functions of CD40, playing an important role in protection from MS development [38].